Skip to main content
Fig. 2 | Radiation Oncology

Fig. 2

From: A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma

Fig. 2

Renal Function. a Functional contribution of both kidneys pre- and 12 weeks post-SABR with corresponding measured GFR values listed above each bar. Numbered bars indicate % contribution from ipsilateral kidney. b Comparison of creatinine clearance (CrCl) calculated using the Cockroft-Gault equation before and after stereotactic ablative radiotherapy (SABR) for patients with available pre- and post-SABR data (n = 9). P-value reported from the Wilcoxon signed-rank test

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us